-
1
-
-
85119556944
-
Historical perspective.
-
FO. Kelsey Historical perspective. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
-
(1997)
-
-
Kelsey, FO.1
-
2
-
-
85119556212
-
Characterization of embryopathy risks.
-
BA. Hill Characterization of embryopathy risks. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
-
(1997)
-
-
Hill, BA.1
-
3
-
-
0027304271
-
The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
-
EP Sampaio G Kaplan A Miranda JA Nery CP Miguel SM Viana EN. Sarno The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum J Infect Dis 168 1993 408 414
-
(1993)
J Infect Dis
, vol.168
, pp. 408-414
-
-
Sampaio, EP1
Kaplan, G2
Miranda, A3
Nery, JA4
Miguel, CP5
Viana, SM6
Sarno, EN.7
-
4
-
-
85119557787
-
Current issues and overview.
-
J. Woodcock Current issues and overview. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
-
(1997)
-
-
Woodcock, J.1
-
5
-
-
0028840974
-
Thalidomide as salvage therapy for chronic graft-versus-host disease
-
PM Parker N Chao A Nademanee MR O'Donnell GM Schmidt DS Snyder AS Stein EP Smith A Molina DE Stepan A Kashyap I Planas R Spielberger G Somlo K Margolin K Zwingenberger K Wilsman RS Negrin GD Long JC Niland KG Blume SJ. Forman Thalidomide as salvage therapy for chronic graft-versus-host disease Blood 86 1995 3604 3609
-
(1995)
Blood
, vol.86
, pp. 3604-3609
-
-
Parker, PM1
Chao, N2
Nademanee, A3
O'Donnell, MR4
Schmidt, GM5
Snyder, DS6
Stein, AS7
Smith, EP8
Molina, A9
Stepan, DE10
Kashyap, A11
Planas, I12
Spielberger, R13
Somlo, G14
Margolin, K15
Zwingenberger, K16
Wilsman, K17
Negrin, RS18
Long, GD19
Niland, JC20
Blume, KG21
Forman, SJ.22
more..
-
7
-
-
0031937242
-
Recalcitrant pyoderma gangrenosum: treatment with thalidomide
-
MS Hecker MG. Lebwohl Recalcitrant pyoderma gangrenosum: treatment with thalidomide J Am Acad Dermatol 38 1998 490 491
-
(1998)
J Am Acad Dermatol
, vol.38
, pp. 490-491
-
-
Hecker, MS1
Lebwohl, MG.2
-
9
-
-
0027441787
-
Chronic cutaneous lupus erythematosus treated with thalidomide
-
AL Holm KE Bowers TO McMeekin AA. Gaspari Chronic cutaneous lupus erythematosus treated with thalidomide Arch Dermatol 129 1993 1548 1550
-
(1993)
Arch Dermatol
, vol.129
, pp. 1548-1550
-
-
Holm, AL1
Bowers, KE2
McMeekin, TO3
Gaspari, AA.4
-
10
-
-
0028879351
-
Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide
-
TG Berger C Hoffman MD. Thieberg Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide J Am Acad Dermatol 33 1995 837 838
-
(1995)
J Am Acad Dermatol
, vol.33
, pp. 837-838
-
-
Berger, TG1
Hoffman, C2
Thieberg, MD.3
-
11
-
-
0030942835
-
A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers
-
LN Alexander CM. Wilcox A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers AIDS Res Hum Retroviruses 13 1997 301 304
-
(1997)
AIDS Res Hum Retroviruses
, vol.13
, pp. 301-304
-
-
Alexander, LN1
Wilcox, CM.2
-
12
-
-
0029800251
-
Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial
-
G Reyes-Teran JG Sierra-Madero V Martinez del Cerro H Arroyo-Figueroa A Pasquetti JJ Calva GM. Ruiz-Palacios Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial AIDS 10 1996 1501 1507
-
(1996)
AIDS
, vol.10
, pp. 1501-1507
-
-
Reyes-Teran, G1
Sierra-Madero, JG2
Martinez del Cerro, V3
Arroyo-Figueroa, H4
Pasquetti, A5
Calva, JJ6
Ruiz-Palacios, GM.7
-
13
-
-
0029811736
-
Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide [discussion 504–505]
-
RA Soler M Howard NS Brink D Gibb RS Tedder D Nadal Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide [discussion 504–505] Clin Infect Dis 23 1996 501 503
-
(1996)
Clin Infect Dis
, vol.23
, pp. 501-503
-
-
Soler, RA1
Howard, M2
Brink, NS3
Gibb, D4
Tedder, RS5
Nadal, D6
-
15
-
-
0032943707
-
New chemotherapy options for the treatment of malignant gliomas
-
E Burton M. Prados New chemotherapy options for the treatment of malignant gliomas Curr Opin Oncol 11 1999 157 161
-
(1999)
Curr Opin Oncol
, vol.11
, pp. 157-161
-
-
Burton, E1
Prados, M.2
-
16
-
-
0031583764
-
Thalidomide in Crohn's disease
-
AR Wettstein AP. Meagher Thalidomide in Crohn's disease Lancet 350 1997 1445 1446
-
(1997)
Lancet
, vol.350
, pp. 1445-1446
-
-
Wettstein, AR1
Meagher, AP.2
-
18
-
-
0026080801
-
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
-
EP Sampaio EN Sarno R Galilly ZA Cohn G. Kaplan Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes J Exp Med 173 1991 699 703
-
(1991)
J Exp Med
, vol.173
, pp. 699-703
-
-
Sampaio, EP1
Sarno, EN2
Galilly, R3
Cohn, ZA4
Kaplan, G.5
-
19
-
-
0033529049
-
Infliximab for the treatment of fistulas in patients with Crohn's disease
-
DH Present P Rutgeerts S Targan SB Hanauer L Mayer RA van Hogezand DK Podolsky BE Sands T Braakman KL DeWoody TF Schaible SJH. van Deventer Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
-
(1999)
N Engl J Med
, vol.340
, pp. 1398-1405
-
-
Present, DH1
Rutgeerts, P2
Targan, S3
Hanauer, SB4
Mayer, L5
van Hogezand, RA6
Podolsky, DK7
Sands, BE8
Braakman, T9
DeWoody, KL10
Schaible, TF11
van Deventer, SJH.12
-
20
-
-
0030954732
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
-
SR Targan SB Hanauer SJH van Deventer L Mayer DH Present T Braakman KL DeWoody TF Schaible PJ Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease N Engl J Med 337 1997 1029 1035
-
(1997)
N Engl J Med
, vol.337
, pp. 1029-1035
-
-
Targan, SR1
Hanauer, SB2
van Deventer, SJH3
Mayer, L4
Present, DH5
Braakman, T6
DeWoody, KL7
Schaible, TF8
Rutgeerts, PJ9
-
21
-
-
0031043778
-
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
-
WA Stack SD Mann AJ Roy P Heath M Sopwith J Freeman G Holmes R Long A Forbes MA. Kamm Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease Lancet 349 1997 521 524
-
(1997)
Lancet
, vol.349
, pp. 521-524
-
-
Stack, WA1
Mann, SD2
Roy, AJ3
Heath, P4
Sopwith, M5
Freeman, J6
Holmes, G7
Long, R8
Forbes, A9
Kamm, MA.10
-
22
-
-
0032714405
-
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
-
EA Vasiliauskas LY Kam MT Abreu-Martin PV Hassard KA Papadakis H Yang JB Zeldis SR. Targan An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease Gastroenterology 117 1999 1278 1287
-
(1999)
Gastroenterology
, vol.117
, pp. 1278-1287
-
-
Vasiliauskas, EA1
Kam, LY2
Abreu-Martin, MT3
Hassard, PV4
Papadakis, KA5
Yang, H6
Zeldis, JB7
Targan, SR.8
-
23
-
-
0032714591
-
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial
-
ED Ehrenpreis SV Kane LB Cohen RD Cohen SB. Hanauer Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial Gastroenterology 117 1999 1271 1277
-
(1999)
Gastroenterology
, vol.117
, pp. 1271-1277
-
-
Ehrenpreis, ED1
Kane, SV2
Cohen, LB3
Cohen, RD4
Hanauer, SB.5
-
24
-
-
0029004771
-
Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmem-brane TNF-alpha and activates immune effector functions
-
BJ Scallon MA Moore H Trinh DM Knight J. Ghrayeb Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmem-brane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
-
(1995)
Cytokine
, vol.7
, pp. 251-259
-
-
Scallon, BJ1
Moore, MA2
Trinh, H3
Knight, DM4
Ghrayeb, J.5
-
25
-
-
0027230553
-
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
-
AL Moreira EP Sampaio A Zmuidzinas P Frindt KA Smith G. Kaplan Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J Exp Med 177 1993 1675 1680
-
(1993)
J Exp Med
, vol.177
, pp. 1675-1680
-
-
Moreira, AL1
Sampaio, EP2
Zmuidzinas, A3
Frindt, P4
Smith, KA5
Kaplan, G.6
-
26
-
-
0031573214
-
Inhibition of IL-12 production by thalidomide
-
DR Moller M Wysocka BM Greenlee X Ma L Wahl DA Flockhart G Trinchiari CL. Karp Inhibition of IL-12 production by thalidomide J Immunol 159 1997 5157 5161
-
(1997)
J Immunol
, vol.159
, pp. 5157-5161
-
-
Moller, DR1
Wysocka, M2
Greenlee, BM3
Ma, X4
Wahl, L5
Flockhart, DA6
Trinchiari, G7
Karp, CL.8
-
27
-
-
0030851993
-
Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis
-
MF. McCarty Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis Med Hypotheses 49 1997 123 131
-
(1997)
Med Hypotheses
, vol.49
, pp. 123-131
-
-
McCarty, MF.1
-
28
-
-
0033021866
-
Protein kinase C–dependent effects on leukocyte migration of thalidomide
-
C Meierhofer S Dunzendorfer CJ Wiedermann Protein kinase C–dependent effects on leukocyte migration of thalidomide J Infect Dis 180 1999 216 219
-
(1999)
J Infect Dis
, vol.180
, pp. 216-219
-
-
Meierhofer, C1
Dunzendorfer, S2
Wiedermann, CJ3
-
30
-
-
0032922147
-
S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide
-
JB Zeldis BA Williams SD Thomas ME. Elsayed S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide Clin Ther 21 1999 319 330
-
(1999)
Clin Ther
, vol.21
, pp. 319-330
-
-
Zeldis, JB1
Williams, BA2
Thomas, SD3
Elsayed, ME.4
-
31
-
-
85119558793
-
Preventing birth defects due to thalidomide exposure.
-
AA. Mitchell Preventing birth defects due to thalidomide exposure. Thalidomide: potential benefits and risk. Open Public Scientific Workshop September 9, 1997 National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention Bethesda, MD
-
(1997)
-
-
Mitchell, AA.1
-
32
-
-
0027979817
-
Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients
-
S Ochonisky J Verroust S Bastuji-Garin R Gherardi J. Revuz Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients Arch Dermatol 130 1994 66 69
-
(1994)
Arch Dermatol
, vol.130
, pp. 66-69
-
-
Ochonisky, S1
Verroust, J2
Bastuji-Garin, S3
Gherardi, R4
Revuz, J.5
|